BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 32866413)

  • 1. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
    Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
    Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a Deep Learning-Based Model to Predict Lung Cancer Risk Using Chest Radiographs and Electronic Medical Record Data.
    Raghu VK; Walia AS; Zinzuwadia AN; Goiffon RJ; Shepard JO; Aerts HJWL; Lennes IT; Lu MT
    JAMA Netw Open; 2022 Dec; 5(12):e2248793. PubMed ID: 36576736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
    Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
    EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
    Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
    PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep Learning to Assess Long-term Mortality From Chest Radiographs.
    Lu MT; Ivanov A; Mayrhofer T; Hosny A; Aerts HJWL; Hoffmann U
    JAMA Netw Open; 2019 Jul; 2(7):e197416. PubMed ID: 31322692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
    Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
    PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection criteria for lung-cancer screening.
    Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
    N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.
    Katki HA; Kovalchik SA; Petito LC; Cheung LC; Jacobs E; Jemal A; Berg CD; Chaturvedi AK
    Ann Intern Med; 2018 Jul; 169(1):10-19. PubMed ID: 29800127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.
    Liao W; Coupland CAC; Burchardt J; Baldwin DR; ; Gleeson FV; Hippisley-Cox J
    Lancet Respir Med; 2023 Aug; 11(8):685-697. PubMed ID: 37030308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
    Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
    Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
    Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
    JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep Learning to Estimate Biological Age From Chest Radiographs.
    Raghu VK; Weiss J; Hoffmann U; Aerts HJWL; Lu MT
    JACC Cardiovasc Imaging; 2021 Nov; 14(11):2226-2236. PubMed ID: 33744131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Second Primary Lung Cancer After Low-Dose Computed Tomography vs Chest Radiography Screening in Survivors of Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Cramer JD; Grauer J; Sukari A; Nagasaka M
    JAMA Otolaryngol Head Neck Surg; 2021 Dec; 147(12):1071-1078. PubMed ID: 34709369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer.
    Choi E; Sanyal N; Ding VY; Gardner RM; Aredo JV; Lee J; Wu JT; Hickey TP; Barrett B; Riley TL; Wilkens LR; Leung AN; Le Marchand L; Tammemägi MC; Hung RJ; Amos CI; Freedman ND; Cheng I; Wakelee HA; Han SS
    J Natl Cancer Inst; 2022 Jan; 114(1):87-96. PubMed ID: 34255071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of lung cancer risk model (PLCO
    Lebrett MB; Balata H; Evison M; Colligan D; Duerden R; Elton P; Greaves M; Howells J; Irion K; Karunaratne D; Lyons J; Mellor S; Myerscough A; Newton T; Sharman A; Smith E; Taylor B; Taylor S; Walsham A; Whittaker J; Barber PV; Tonge J; Robbins HA; Booton R; Crosbie PAJ
    Thorax; 2020 Aug; 75(8):661-668. PubMed ID: 32631933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
    Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
    Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.